Virtu Financial LLC Acquires Shares of 29,144 Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Virtu Financial LLC acquired a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 29,144 shares of the company’s stock, valued at approximately $802,000.

Several other large investors have also bought and sold shares of NTLA. Blue Trust Inc. bought a new stake in shares of Intellia Therapeutics in the 4th quarter worth approximately $26,000. Signaturefd LLC boosted its position in shares of Intellia Therapeutics by 89.3% in the 4th quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock worth $49,000 after purchasing an additional 751 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in shares of Intellia Therapeutics by 35.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock worth $93,000 after purchasing an additional 793 shares in the last quarter. EntryPoint Capital LLC boosted its position in shares of Intellia Therapeutics by 61.1% in the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock worth $113,000 after purchasing an additional 1,563 shares in the last quarter. Finally, Spire Wealth Management boosted its position in shares of Intellia Therapeutics by 3,789.0% in the 4th quarter. Spire Wealth Management now owns 3,889 shares of the company’s stock worth $119,000 after purchasing an additional 3,789 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $23.85 on Friday. Intellia Therapeutics, Inc. has a one year low of $19.37 and a one year high of $40.98. The business has a fifty day moving average price of $24.31 and a 200-day moving average price of $25.41.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($1.06) EPS for the quarter, topping the consensus estimate of ($1.35) by $0.29. The company had revenue of $28.94 million during the quarter, compared to analysts’ expectations of $15.60 million. Equities research analysts anticipate that Intellia Therapeutics, Inc. will post -4.98 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Citigroup decreased their price objective on shares of Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Friday, May 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 24th. Wedbush restated a “neutral” rating and issued a $29.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, April 23rd. Truist Financial restated a “buy” rating and issued a $120.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 24th. Finally, StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a report on Thursday, June 27th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $69.00.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.